Search International and National Patent Collections

1. (WO2018178925) DOSE AND REGIMEN FOR AN HDM2-P53 INTERACTION INHIBITOR IN HEMATOLOGICAL TUMORS

Pub. No.:    WO/2018/178925    International Application No.:    PCT/IB2018/052187
Publication Date: Fri Oct 05 01:59:59 CEST 2018 International Filing Date: Fri Mar 30 01:59:59 CEST 2018
IPC: A61K 31/506
A61K 45/06
A61P 35/02
Applicants: NOVARTIS AG
Inventors: FERRETTI, Stephane
GUERREIRO, Nelson
JEAY, Sebastien
JULLION, Astrid
MEILLE, Christophe
WUERTHNER, Jens
Title: DOSE AND REGIMEN FOR AN HDM2-P53 INTERACTION INHIBITOR IN HEMATOLOGICAL TUMORS
Abstract:
The present invention relates to the HDM2-p53 interaction inhibitors (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one (HDM201), or a pharmaceutically acceptable non-covalent derivative thereof, for use in the treatment of patients with hematological tumors, wherein the drug is administered by an extended low dose dosing regimen.